Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9847093 | 0.84 | CBFB (0.46) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL4069917 | 0.82 | CBFB (0.45) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL23227712 | 0.82 | CBFB (0.45) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL6755343 | 0.81 | CBFB (0.44) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL6757251 | 0.81 | CBFB (0.44) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL6756153 | 0.79 | KDM4E (0.44) | CBFBOPRM1EGLN1ADAMTS5NPC1 | |
| SCHEMBL7409334 | 0.79 | MGAM (0.49) | CBFBALDH1A1GAA | |
| SCHEMBL6759191 | 0.78 | GAA (0.54) | CBFBNPC1RAB9AALDH1A1GAA | |
| SCHEMBL6756137 | 0.78 | CBFB (0.42) | CBFBOPRM1ADAMTS5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7416048 | 0.77 | MGAM (0.47) | CBFBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401836-B1 | IMIDAZO¬1,2-A|PYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES VIRAL INFECTIONS | SMITHKLINE BEECHAM CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | GUDMUNDSSON KRISTJAN | 2006-07-27 | — | — | US | disclosed |
| EP-1432712-B1 | IMIDAZO-PYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HERPES VIRAL INFECTION | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1176959-B1 | NOVEL PROLINES AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6579894-B2 | Bactericides, fungicides | MERCK & CO., INC. | 2003-06-17 | — | — | US | disclosed |
| US-20030013724-A1 | Novel prolines as antimicrobial agents | HAMMOND MILTON L (US) | 2003-01-16 | — | — | US | disclosed |
| EP-1176959-A4 | NOVEL PROLINES AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-6417217-B1 | TREATING INFECTIONS WITH HETEROCYCLIC MICROBIOCIDES THIS INVENTION RELATES TO THE FIELD OF TRANSFER RIBONUCLEIC ACID (TRNA) SYNTHETASE INHIBITORS, THEIR PREPARATION AND THEIR USE AS ANTIMICROBIAL ADMINISTERING TO THE SUBJECT A | MERCK & CO., INC. | 2002-07-09 | — | — | US | disclosed |
| EP-1176959-A1 | NOVEL PROLINES AS ANTIMICROBIAL AGENTS | Merck & Co., Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6333344-B1 | ENZYME INHIBITORS AND BACTERICIDES | MERCK & CO. | 2001-12-25 | — | — | US | disclosed |
| WO-2000066119-A1 | NOVEL PROLINES AS ANTIMICROBIAL AGENTS | MERCK & CO., INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013724-A1 | Novel prolines as antimicrobial agents | AARS1, EPRS1, TRMT1 | CBFB 2979/4885OPRM1 679/4885EGLN1 780/4885 |
| US-20060167252-A1 | Imidazo[1,2-a]pyridine derivatives for treatment of herpes viral infections | IRF3, IFNAR1, IL2 | CBFB 829/4885OPRM1 3695/4885EGLN1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.